
dec pm et
summari global supplier over-the-counter over-the-count non-prescript health care product
gener pharmaceut
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
plc lower
target price ep
estim long-term
averag forward price-to-earnings due elev risk
see aris recent notic larg tax
assess maintain
ep estim share
around today compani report
irish offic revenu
commiss gave notic owe tax
total euro relat transact
execut subsidiari pharma current
cash equival total
believ incom relat transact
appropri report trade incom
tax disput
commiss claim transact
treat gain tax
appeal assess payment
due process complet
could take year remain neutral
share due uncertainti around
whether pay larg tax
risk assess reflect view produc
mani commodity-lik product leav limit abil
control price also see focu suppli
store-label over-the-counter product limit long-term
growth often perceiv lower
qualiti brand view think consum
percept qualiti import health care
product especi economi well
shopper better-posit opt brand over-the-counter
product risk somewhat mitig
larg market share on-going restructur focu
higher-valu product
feb ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview lead global health care supplier develop manufactur
distribut over-the-count over-the-counter prescript pharmaceut nutrit product activ
pharmaceut ingredi api consum product world largest manufactur
over-the-counter pharmaceut product privat label store brand market store brand product contain
activ ingredi advertis brand lower cost consum store brand
retail sell product store anoth chosen brand name
consum product compris broad line over-the-counter store brand product compar qualiti efficaci
advertis brand product cost retail store brand product significantli lower
compar nation advertis brand name product retail therefor price store
brand product compet nation brand product yet realiz greater profit margin store
major consum product categori includ analges cough/cold/allergy/sinu medic
gastrointestin smoke cessat item exampl store brand analges acetaminophen
activ ingredi brand tylenol consum product also includ broad rang household
product includ cosmet toiletri deterg bar soap sold carelin neca
gener busi focus develop manufactur sale gener prescript
pharmaceut primarili market manufactur oper base israel
spray liquid suspens solut well nasal spray oral liquid transderm product
compani also manufactur market brand prescript drug licens firm
pharmaceut medic diagnost product import israel exclus
agreement primarili chemagi busi manufactur complex chemic
activ pharmaceut ingredi api use world-wide gener drug industri certain
ingredi also use pharmaceut product api facil israel germani
china nutrit compris infant formula product infant toddler food oral electrolyt
solut product well vitamin miner dietari supplement product
compani sell product chain drug store wholesal distributor hospit system
group purchas organ well retail drug supermarket mass merchandis chain
also collabor agreement
cobrek pharmaceut
impact major develop march sold tysabri royalti right royalti pharma
bilion plu potenti payment royalti earn meet
specifi threshold think price low end note declin tysabri sale
competit multipl sclerosi market tysabri gener million million royalti
gener busi augment juli acquisit paddock laboratori
million cash februari purchas million
expans veterinari product facilit acquisit sergeant pet
million septemb velcera million april decemb acquir
corpor billion subsequ re-loc corpor headquart ireland
believ lower corpor tax rate ireland enabl compani save million tax
annual march acquir omega pharma nv billion omega develop
over-the-count product annual sale billion
financi trend sale aid primarili acquisit rose
billion billion repres three-year compound annual growth
rate compound-annual-growth-rate follow omega acquisit sale rose sale adjust
ep declin partli due sale tysabri royalti stream right
march encount slow sale consum healthcar unit
chairman board
global oper
senior director
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
under-valued
neutral sinc novemb technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
e-estim na-not avail nm-not meaning nr-not rank ur-und review prior fiscal year end jun
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook pharmaceut sub-industri
next month posit view
reflect strong novel drug approv activ
see fda posit
brand drug maker repres
lion share sub-industri market
cap view temper expect
continu pressur gener drug price
neg gener drug maker lower
growth overal prescript volum
far year-over-year increas
brand drug price per prescript
around accord iqvia estim
aid strong novel drug approv activ
fda particularli weak year
novel drug approv number
rebound pace
strong growth well approv alreadi
made octob expect strong
pace novel drug approv brand drug
price inflat continu next year
aid estim approxim
year-over-year growth brand pharma
spend year end june
side coin
outlook gener drug price mostli
neg growth gener drug price
averag around neg far
dont expect major near-term
revers trend toward posit price
growth think deflationari trend
mostli driven robust gener drug
approv activ fda custom
consolid rather polit
total gener drug approv hit record
grow year-over-year
increas competit exist gener
view bring price pace
gener approv seem moder
howev approv
august versu
expect moder
deflat howev bring full-on
gener inflat due view
purchas joint ventur
three major drug distributor three largest
 retail pharmaci limit gener maker
abil rais drug price environ
joint ventur account
gener sale estim includ
cardin
walgreen
beyond drug price think prescript
volum growth fall
next year strong gain health insur
growth think
gain harder come
next year unemploy near
all-tim low remov tailwind
prescript volum growth go forward
view assum slower growth
number peopl enrol health insur
plan gener mean slower growth
use total enrol figur eight
largest health insur proxi
estim number individu
famili health insur grew
growth slow
coincid roughli growth
prescript volum far versu
accord iqvia estim
expect slow next year
increas versu rise
composit index year-to-d
octob
rise composit index
base index
five-year market price perform dec
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
rose howev prescript pharmaceut sale
expect partli due price eros suppli disrupt new product
scopolamin launch believ re-launch
scopolamin along anticip launch gener proair
although cautiou prescript pharmaceut unit
encourag improv consum healthcar unit america
oper margin improv bp unit saw
oper margin improv bp share lower today
trade ep estim peer attract
valu view /jeffrey loo cfa
keep target line peer
ep estim near mid-point five-year rang
set ep vs ahead
estim forma sale modestli segment show posit
growth encourag result appear restructur
includ sale asset gener posit result expect new
ceo uwe roehrhoff evalu strateg plan provid flat modest
sale growth wide ep rang /jeffrey loo cfa
share significantli reschedul
earn releas slate today state need addit time
complet final incom tax review procedur relat reconcili
non-cash item new date given howev provid preliminari
sale line forecast state gener net sale
segment guidanc also state oper cash flow
compani guidanc base metric believ earn
line forecast /jeffrey loo cfa
analyst research note compani news
pm et cfra keep hold opinion share perrigo compani plc
lower target price
ep estim long-term averag forward price-to-earnings due
elev risk see aris recent notic larg tax assess
maintain ep estim share around
today compani report irish offic revenu
commiss gave notic owe tax total euro relat
transact execut subsidiari pharma current cash equival
total believ incom relat transact
appropri report trade incom tax disput
commiss claim transact treat gain tax
appeal assess payment due
process complet could take year remain neutral
share due uncertainti around whether pay larg tax
lower target ep
estim long-term averag forward price-to-earnings expect
below-averag ep growth result challeng gener unit
drop ep estim
faster-than-expect deterior gener busi sale
yoy gross profit margin fell approxim bp worst perform
quarter gener segment revenu saw sale
declin yoy sustain downward trend sinc increas
competit custom consolid drive declin
announc august plan exit busi although
still remain unclear form exit take adjust pre-tax incom
first nine month yoy much reason
believ better point given weak sale outlook
margin pressur compani face /colin scarola
keep target price below-p
forward ep estim reflect view
compani like continu face challeng particularli relat
recent tysabri sale howev posit news
spin-off prescript pharmaceut busi sale
focu consum busi also see increas stabil recent
manag chang keep ep estim
respect trade near estim fair valu expect
share outperform broader market next month /jim
et cfra lower opinion share compani plc
hold buy lower target price
below-p forward ep estim see
challeng consum busi particularli anim health unit
price eros prescript pharmaceut unit ep vs
estim lower ep estim
ep estim sale fell consum
fx benefit rose prescript pharmaceut sale fell
separ announc separ prescript
pharmaceut unit spin-off sale merger
prescript pharmaceut unit account sale
highest oper margin unit compar
consum healthcar unit /jeffrey loo cfa
buy hold keep target
line peer ep estim ep vs
ahead view consum healthcar america sale rose
consum healthcar sale aid fx benefit
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd
repres total revenu estim
fiscal year analyst estim earn
per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
